ORGANIC
LETTERS
2009
Vol. 11, No. 13
2760-2763
An Oxazolo[3,2-b]indazole Route to
1H-Indazolones†
James S. Oakdale,‡ Danielle M. Solano,‡ James C. Fettinger,‡
Makhluf J. Haddadin,§ and Mark J. Kurth*,‡
Department of Chemistry, UniVersity of California, One Shields AVenue, DaVis, California 95616, and
Department of Chemistry, American UniVersity of Beirut, Beirut, Lebanon
mjkurth@ucdaVis.edu
Received April 24, 2009
ABSTRACT
The novel heterocycle 2,3-dihydrooxazolo[3,2-b]indazole has been synthesized and utilized to provide easy access to 1H-indazolones, particularly
the previously unreported 2-(2-alkoxyethyl)-1H-indazol-3(2H)-ones. Mechanistic as well as optimization and reaction scope studies are reported.
1H-Indazol-3(2H)-ones (1, Scheme 1 inset) are known to
exhibit a wide range of biologically and pharmaceutically
Scheme 1
.
Formation of 1H-Indazolone 3a along with
2H-Indazole 4a
relevant properties and are reported to exhibit analgesic,1
antitumor,2 anticancer,3 and anti-inflammatory activities.4
Due in part to these wide ranging biological implications, a
number of techniques for synthesizing indazolones have been
reported.5 These include such strategies as base-mediated
ring opening of pyrazoles,4 base-mediated intramolecular ipso
substitution of 2-fluorobenzohydrazides,3 PIFA-mediated
intramolecular N-acylnitrenium trapping,6 acid-induced rear-
rangement of azobenzenes,7 o-azidobenzanilide treatment
with thionyl chloride followed by base-mediated hydrolysis,1
† Dedicated to the memory of Professor Aaron Mills (University of
Idaho), deceased May 2009.
‡ University of California.
§ American University of Beirut.
(1) Fletcher, S. R.; McIver, E.; Lewis, S.; Burkamp, F.; Leech, C.;
Mason, G.; Boyce, S.; Morrison, D.; Richards, G.; Sutton, K.; Jones, A. B.
Bioorg. Med. Chem. Lett. 2006, 16, 2872–2876.
(2) Wang, H.; Han, H.; Von Hoff, D. D. Cancer Res. 2006, 66, 9722–
9730.
zinc/sodium hydroxide reductive cyclization of 2-nitroben-
zamides,8 copper-mediated C-N bond-forming heterocy-
clization of 2-halohydrazides,9 protection of the N-2 position
followed by alkylation/deprotection,8b CuO-catalyzed cou-
(3) Kawanishi, N.; Sugimoto, T.; Shibata, J.; Nakamura, K.; Masutani,
K.; Ikuta, M.; Hirai, H. Bioorg. Med. Chem. Lett. 2006, 16, 5122–5126.
(4) Abouzid, K. A. M.; El-Abhar, H. S. Arch. Pharmacal Res. 2003,
26, 1–8.
(5) For a review, see: Baiocchi, L.; Corsi, G.; Palazzo, G. Synthesis
1978, 633–648.
(8) (a) Bird, C. W.; Chng, J. C. W.; Rama, N. H.; Saeed, A. Synth.
Commun. 1991, 21, 545–548. (b) Bruneau, P.; Delvare, C.; Edwards, M. P.;
McMillan, R. M. J. Med. Chem. 1991, 34, 1028–1036.
(9) Tanimori, S.; Ozaki, Y.; Iesaki, Y.; Kirihata, M. Synlett 2008, 1973–
1976.
(6) Correa, A.; Tellitu, I.; Dom´ınguez, E.; SanMartin, R. J. Org. Chem.
2006, 71, 3501–3505.
(7) Peters, M. V.; Stoll, R. S.; Goddard, R.; Buth, G.; Hecht, S. J. Org.
Chem. 2006, 71, 7840–7845.
10.1021/ol900891s CCC: $40.75
Published on Web 06/08/2009
2009 American Chemical Society